Matthias Scheffler

13PUBLICATIONS

172CO-AUTHORS

Predictive and prognostic markersMolecular targetsGene expression (incl. microarray and other genome-wide approaches)Cancer therapy (excl. chemotherapy and radiation therapy)

Get your video featured.

Publish with JoVE

Get your video featured.

Publish with JoVE

Publications (13)

Sort by Publication Date:

|Jun 10, 2026

Molecular and clinical characteristics of patients with non-small cell lung cancer (NSCLC) harboring KRAS Q61 mutations to assess therapeutic responses.

|Dec 19, 2025

Molecular and Clinical Characteristics of Patients with Non-Small Cell Lung Cancer Harboring KRAS G12V Mutations.

Felix John, Lea Ruge, Malte Verheyen

|Feb 27, 2025

Author Correction: CTLA4 blockade abrogates KEAP1/STK11-related resistance to PD-(L)1 inhibitors.

Ferdinandos Skoulidis, Haniel A Araujo, Minh Truong Do

|Nov 11, 2024

Benchmark of screening markers for KEAP1/NFE2L2 mutations and joint analysis with the K1N2-score.

Christoph Arolt, Andreas H Scheel, Margaret Dugan

|Oct 09, 2024

CTLA4 blockade abrogates KEAP1/STK11-related resistance to PD-(L)1 inhibitors.

Ferdinandos Skoulidis, Haniel A Araujo, Minh Truong Do

|Apr 20, 2023

Durable Response With Sequential Tyrosine Kinase Inhibitor Treatment in a Patient With ROS1 Fusion-Positive Pancreatic Adenocarcinoma: A Case Report.

Theresa Reutter, Jana Fassunke, Michael Püsken

Pageof 3

Frequent Collaborators

Reinhard Büttner

Jürgen Wolf

Marcelo V Negrao

Richard Lee

Teng Zhou

Jonathan W Goldman

Lucia Nogova

Ying Ni

Collin M Blakely

Anna Kron

Frequent Collaborators

Reinhard Büttner

Jürgen Wolf

Marcelo V Negrao

Richard Lee